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Objectives The purpose of this study was to evaluate the long-term effects of distal protection during percutaneous coro-
nary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).
Background The use of distal filter protection during primary PCI increases procedure complexity and may influence lesion
treatment and stent implantation.
Methods The STEMI patients were assigned to distal protection (DP) (n  312) or conventional treatment (CT) (n  314).
Clinical follow-up was performed after 1, 6, and 15 months, and angiographic follow-up after 8 months. All tar-
get lesion revascularizations (TLRs) were clinically driven. We report the pre-specified end points of stent throm-
bosis according to the criteria of the Academic Research Consortium, TLR, and reinfarction after 15 months.
Results The total number of stent thrombosis was 11 in the DP group and 4 in the CT group (p  0.06). The rate of defi-
nite stent thrombosis was significantly increased in the DP group as compared with the CT group, with 9 cases
versus 1 (p  0.01). Clinically driven TLRs (31 patients vs. 18 patients, p  0.05) and clinically driven target ves-
sel revascularizations (37 patients vs. 22 patients, p  0.04) were more frequent in the DP group.
Conclusions In primary PCI for STEMI, the routine use of DP increased the incidence of stent thrombosis and clinically driven
target lesion/vessel revascularization during 15 months of follow-up. (Drug Elution and Distal Protection in ST
Elevation Myocardial Infarction Trial [DEDICATION]; NCT00192868) (J Am Coll Cardiol 2010;55:867–71)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.09.052j
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dhe DEDICATION (Drug Elution and Distal Protection in
T Elevation Myocardial Infarction) trial, evaluating the po-
ential benefit of distal protection (DP) using a filter wire as an
djunctive to conventional treatment (CT) during primary
ercutaneous coronary intervention (PCI), found no benefit
ith respect to either primary or secondary end points (1).
Previous studies have similarly failed to show imme-
iate, short-, or intermediate-term benefits of the ad-
rom the *Department of Cardiology, Aarhus University Hospital, Skejby, Denmark;
nd the †Department of Cardiology, Copenhagen University Hospital, Rigshospita-
et, Copenhagen, Denmark.l
Manuscript received July 13, 2009; revised manuscript received September 4, 2009,
ccepted September 14, 2009.unctive device (2– 4), but potential long-term effects
ave not been reported.
In the DEDICATION trial, we also evaluated the
ffect of drug-eluting stents (DES) versus bare-metal
tents (BMS), and therefore, we followed up all patients
or 15 months (5). In the present study, we report
re-specified long-term end points of stent thrombosis,
arget lesion revascularization (TLR), and target vessel
evascularization (TVR), reinfarction of the infarct-
elated artery, and death after 15 months.
ethods
tudy design. The design of the DEDICATION trial was
escribed previously (1,5). In brief, patients with symptomsasting 12 h and with ST-segment elevation 0.2 mV in
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ble for enrollment. The study
protocol was approved by the
local ethics committees, and all
patients gave written informed
consent.
Randomization and procedures.
Patients were pre-treated with
300 mg aspirin, 300 to 600 mg
clopidogrel, and 10,000 IU un-
fractionated heparin. A guide
wire was advanced through the
lesion, and pre-dilation was per-
formed to visualize the periph-
eral vascular bed. If the operator
predicted that a filter wire (EZ-
Filter Wire, Boston Scientific,
Natick, Massachusetts) or a Spi-
derX protection device (eV3,
Inc., Minneapolis, Minnesota)
could be advanced, randomiza-
tion was performed stratified
ith regard to sex and diabetes mellitus.
ollow-up schedule. Clinical follow-up was performed at
and 6 months, and angiographic follow-up at 8 months.
he TLR was considered clinically driven in case of angina
nd a diameter stenosis50%, and in any case of a diameter
tenosis 70%. A final clinical follow-up was performed at
5 months, 3 months after cessation of dual-antiplatelet
herapy.
tudy end points. The primary end point was the number
f patients suffering a major adverse cardiac event (MACE),
efined as stent thrombosis, TLR, TVR, nonfatal myocar-
ial reinfarction, or death within 15 months. Stent throm-
osis was characterized according to the Academic Research
onsortium definitions as definite, probable, and possible
6). Myocardial infarction was defined as a total creatine
Abbreviations
and Acronyms
BMS  bare metal stent(s)
CT  conventional
treatment
DES  drug-eluting stent(s)
DP  distal protection
MACCE  major adverse
cardiac and cerebral events
MACE  major adverse
cardiac events
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TLR  target lesion
revascularization
TVR  target vessel
revascularization
Baseline Clinical CharacteristicsTable 1 Baseline Clinical Characteristics
Dist
Age, yrs
Male 23
Diabetes mellitus 2
Hypertension 10
Treatment for hyperlipidemia 5
Current smoker 17
Family history of CAD 11
Previous myocardial infarction 2
Previous PCI/CABG 1
Symptom onset to arrival, min 20
Door-to-balloon, min 2
Symptom onset to balloon, min 23
Baseline cumulated ST-segment deviation, mV 1.Values are median  SD, n (%), or median (range).
CABG  coronary artery bypass graft surgery; CAD  coronary artery diseainase elevation 2 times the upper normal limit with a
oncomitant increase in creatine kinase-myocardial band
ass blood concentration in the presence of an acute
oronary syndrome, and reinfarction was present in case the
ecurrent myocardial infarction could be related (by electro-
ardiography or angiography) to the target vessel. Clinically
riven TLR was defined as revascularization of the target
esion, in the presence of recurrent angina and a significant
tenosis/occlusion of the infarct-related lesion. Nonclini-
ally driven TLR was allowed in the absence of angina
henever the diameter restenosis was 70%. Finally, TVR
as defined as revascularization either in the target lesion or
n an area remote from the target lesion in the same
oronary artery. The Clinical Events Committee adjudi-
ated all serious events and stent thromboses.
tatistical analysis. Analyses were based on intention to
reat. Categorical variables were analyzed by the chi-square
est or by the Fisher exact test. Continuous variables were
nalyzed using the Mann-Whitney U test for unpaired
amples. All p values were 2-sided.
esults
aseline characteristics and procedural results. Baseline
linical and angiographic characteristics of the 626 patients
ere well matched (Tables 1 to 3). Of the patients assigned
o DP, the filter wire was successfully advanced and un-
olded distally to the lesion before stent implantation in 254
f 312 patients (81%). Pre-dilation was performed in 226
atients (71%) before filter placement. For pre-dilation, a
.5-mm balloon was used in 32 patients (10%), a 2.0-mm
alloon in 141 patients (45%), a 2.5-mm balloon in 50
atients (16%), and a 3.0-mm balloon in 3 patients (1%).
he Spider-X system was used in 39 patients. In 58 patients
19%), none of the DP systems could be advanced to a
ufficient landing zone.
tection
12)
Conventional Treatment
(n  314) p Value
2.3 63 12.1 0.27
) 226 (72.0) 0.53
37(11.8) 0.30
) 107 (34.1) 0.61
) 64 (20.4) 0.35
) 158 (50.3) 0.24
) 118 (37.6) 0.80
20 (6.4) 1.0
15 (4.8) 0.62
1,350) 199 (40–996) 0.98
04) 24 (3–92) 0.01
1,370) 222 (60–1,027) 0.55
2.2) 1.3 (0.8–2.1) 0.13al Pro
(n  3
62 1
2 (74.4
8 (9.0)
0 (32.1
8 (18.6
7 (56.7
4 (36.5
0 (6.4)
6 (5.1)
0 (26–
7 (3–1
3 (59–
1 (0.7–se; PCI  percutaneous coronary intervention.
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March 2, 2010:867–71 Increased Rate of Stent Thrombosis After Filter ProtectionACE. STENT THROMBOSIS. The rate of definite stent
hrombosis was significantly increased in the DP group as
ompared with the CT group, with 9 cases versus 1 (p 
.01). The only definite stent thrombosis in the CT group
ccurred at day 1 in a BMS. Of the 9 cases in the DP group
6 in BMS and 3 in DES), 5 occurred within the first
onth, and 4 occurred between 111 and 275 days from the
nitial intervention. The total number of stent thromboses,
ncluding probable and possible, was 11 in the DP group
nd 4 in the CT group (p  0.06) (Table 4).
LR. The rate of TLR was significantly increased in the DP
roup, 39 patients versus 22 patients in the CT group
p  0.02), with a similar finding for the clinically driven
LR, 31 versus 18 patients (p  0.05).
VR. The rate of TVR was significantly increased in the DP
roup, 48 patients versus 26 patients in the CT group
rocedural ResultsTable 3 Procedural Results
Distal
Protection
(n  312)
Conventional
Treatment
(n  314) p Value
Use of GP IIb/IIIa inhibitor 301 (97) 302 (96) 0.36
Filter wire attempted 304 (97) 0 —
Filter wire success 254 (81) 0 —
Stent implanted 307 (98) 312 (99) 0.29
Drug-eluting stent 158 (51) 155 (49) 0.81
Stented length, mm 18 (6–60) 20 (8–107) 0.83
Stent diameter, mm 3.5 (2.0–5.0) 3.5 (2.0–5.0) 0.20
TIMI flow grade III post-procedure 295 (95) 268 (85) 0.01
IABP 4 (1) 6 (2) 0.75
Procedural success 309 (99) 310 (99) 0.69
Baseline Angiographic CharacteristicsTable 2 Baseline Angiographic Characterist
Distal Prot
(n  31
Number of diseased vessels
1-vessel disease 198 (63)
2-vessel disease 83 (27)
3-vessel disease 30 (10)
Infarct-related artery
RCA 139 (45)
LAD 138 (44)
LCX 35 (11)
Baseline TIMI flow grade
0–1 209 (67)
2–3 103 (33)
Angiographic lesion characteristics
Reference vessel diameter, mm 3.50 (2.20
Diameter stenosis, % 100 (30–1
Minimal lumen diameter, mm 0.00 (0.00
Visible thrombus 213 (68)
Values are n (%) or median (range).
LAD  left anterior descending artery; LCX  left circumflex artery;alues are n (%) or median (range).
GP  glycoprotein; IABP  intra-aortic balloon pump; other abbreviation as in Table 2. Vp  0.01), with a similar finding for the clinically driven
VR, 37 patients versus 22 patients (p  0.04).
YOCARDIAL INFARCTION. The rates of myocardial infarc-
ions (9 patients vs. 6 patients) and of reinfarctions (7 patients
s. 3 patients) were not significantly different between the
groups.
EATH. Mortality rates were similar in the 2 groups: 13 deaths
n the DP group and 15 deaths in the CT group (p  NS).
ACE. The number of patients suffering any MACE was
ignificantly increased in the DP group, 59 patients versus
0 patients in the CT group (p  0.04) (Fig. 1).
iscussion
he STEMI patients randomly allocated to adjunctive
herapy with filter protection had no benefit with respect to
mmediate, short-term (30 days), intermediate-term (6
onths), or long-term (15 months) evaluation. On the
ontrary, after 15 months, we found a significantly increased
ate of MACE in the DP group.
With respect to lack of benefit, the results are in accor-
ance with those of previous studies evaluating distal pro-
Conventional Treatment
(n  314) p Value
194 (62)
85 (27) 0.86
34 (11)
152 (48)
119 (38) 0.25
43 (14)
213 (68) 0.87
101 (32)
3.50 (2.30–5.00) 0.25
100 (50–100) 0.17
0.00 (0.00–2.00) 0.20
236 (75) 0.14
right coronary artery; TIMI  Thrombolysis In Myocardial Infarction.
tent ThrombosisTable 4 Stent Thrombosis
Distal
Protection
(n  312)
Conventional
Treatment
(n  314) p Value
Any stent thrombosis 11, 3.5 (1.5–5.6) 4, 1.3 (0.0–2.5) 0.06
Definite stent thrombosis 9, 2.9 (1.0–4.7) 1, 0.3 (0.0–0.9) 0.01
Early (30 days) stent
thrombosis
5, 1.6 (0.2–3.0) 1, 0.3 (0.0–0.9) 0.06
Late stent thrombosis
(30 days)
4, 1.3 (0.0–2.5) 0ics
ection
2)
–5.00)
00)
–3.15)alues are n, % (95% confidence interval).
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Increased Rate of Stent Thrombosis After Filter Protection March 2, 2010:867–71ection during primary PCI (2–4,7). Previous studies have
valuated end points immediately after the procedure, after
0 days, or after 6 months as the longest follow-up period.
ur study is the first to extend follow-up to 15 months,
hereby evaluating long-term outcome.
ncreased rate of stent thrombosis. It is known that early
tent thrombosis (occurring within 30 days) is relatively
ommon with acute coronary syndromes, occurs with sim-
lar frequency after stenting with DES and BMS, and is
redicted by inadequate pharmacotherapy, diffuse athero-
clerosis, and suboptimal angiographic results (8). In the
resent study, patients were treated with dual platelet
nhibition, and as the study was randomized, the 2 groups
ere presumed to be equal with respect to the amount of
iffuse atherosclerosis.
In a study of embolic protection with filter wire during
arotid stenting (9), 7.9% of cases had transient spasm in the
essel and 13.1% had nitroglycerine resistant flow impair-
ent. Vessel diameter and flow were restored after removal
f the filter, which was presumed to be responsible for the
essel spasm and flow impairment. In the present study,
tenting was performed with the filter wire in place, and
lthough the median values of vessel diameter and stent
izes were similar in the 2 groups, we cannot exclude that
he filter wire in single cases might have caused vessel
pasm, leading to an underestimation of the vessel diameter
nd to undersizing of the implanted stent, a known
redictor of early stent thrombosis in acute coronary
yndromes (8).
Dissection of the vessel wall at the site of filter deploy-
ent is another possible source of stent thrombosis (10).
e did not find an increased rate of procedure complica-
ions in the DP group, but we cannot rule out that minor
issections not seen during the procedure while the filter is
xpanded in the vessel might be responsible for an increased
Figure 1 MACE Within 15 Months
Major adverse cardiac events (MACE) within 15 months are shown. The blue
bars indicate distal protection; the red bars indicate conventional treatment.
Def ST  definite stent thrombosis; Re-MI  myocardial infarct in the culprit
vessel; TLR  target lesion revascularization; TVR  target vessel
revascularization.umber of acute and subacute stent thrombosis.
EFinally, it might be speculated as to whether difficulties
uring retrieval of the filter might affect the stent apposition.
ncreased rate of revascularization. An increased number
f patients in the DP group experienced restenosis in the
arget vessel. Most of these occurred in the target lesion, but
lso an increased number of restenosis in the target vessel
utside the treated lesion was seen. The use of a filter for
mbolic protection during primary PCI increases procedure
omplexity. Deployment of the filter may not be a problem
n most cases with simple anatomy, but in cases with
ortuous or calcified vessels or with very tight lesions, it
ight be not only a technical challenge but also associated
ith an increased risk of damaging the vessel. Pre-dilation
ith a small balloon might be necessary to overcome the
roblems in these complex lesions, and in our study, pre-
ilation was performed in 70% of cases. However, pre-
ilation might further increase the risk associated with
lacement of the filter, as minor dissections or intimal
aps created by the dilation might be aggravated when
he filter has to pass through the dilated vessel segment.
herefore, it seems likely that the use of the filter might
ave created areas with damage of the intima, either in
he perilesion area or more remote area.
As previously described for carotid stenting, nitroglycerine-
esistant flow impairment occurred in 10% of cases (9). We
id not register the rate of flow impairment during procedures,
ut it seems likely that at least some of the stents might have
een placed while the visibility of the lesion was compromised,
hereby increasing the risk of misplacing the stent.
Previous studies have suggested that the mechanical
rauma to the artery during angioplasty itself might
ccelerate disease progression and the appearance of new
arrowings in the arteries (11,12). As it must be assumed
hat potential trauma to the artery was more severe in the
P group, that might be another possible explanation
hy repeat revascularization was increased in this group.
onclusions
he present randomized study found no benefit with respect
o short-, intermediate-, or long-term angiographic or
linical end points. On the contrary, we found a significantly
ncreased rate of adverse cardiac events within 15 months in
he group of patients treated with routine DP. Together
ith the results of previous studies evaluating DP, the
esults of the DEDICATION trial demonstrate that rou-
ine use of a filter wire in its present form cannot be
dvocated and probably should be avoided with primary
CI for STEMI.
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